Triamcinolone may be more effective than bevacizumab in patients with DME

This prospective study randomized 32 subjects with diffuse diabetic macular edema (DME) to a single intravitreal injection of triamcinolone acetonide (4 mg/0.1 mL) or bevacizumab (1.25 mg/0.05 mL). One month after treatment, foveal thickness decreased from 452  µ to 299 µ in the IVTA group and from 292 µ to 270 µ in the bevacizumab group. BCVA increased by two or more lines in 58.3% percent of the IVTA group. No eye in the bevacizumab group gained two or more lines, but 50 percent gained one line. A transient increase in IOP occurred in four cases (16.7 percent) in the IVT group, which was successfully controlled with topical medications.   There were no complications in the bevacizumab group.